Werewolf Therapeutics to merge with Ambros in deal valuing target at $500M
Werewolf Therapeutics announced a merger with privately held Ambros Therapeutics, with Ambros stockholders expected to own about 71.7% of the combined company.
What happened
Werewolf Therapeutics, Inc. (Nasdaq: HOWL), a pharmaceutical company based in Waltham, Massachusetts, announced on August 21, 2026, that it has entered into a definitive merger agreement with Ambros Therapeutics, Inc., a privately held company. The merger will be structured as a reverse merger: a wholly owned subsidiary of Werewolf will merge into Ambros, with Ambros surviving as a wholly owned subsidiary of Werewolf.
Under the terms, Ambros stockholders will receive shares of Werewolf common stock, and Werewolf will also issue pre-funded warrants to certain investors. The deal includes a concurrent private placement (PIPE financing) expected to raise at least $100 million. On a pro forma basis, pre-merger Werewolf equity holders are expected to own about 6.8% of the combined company, Ambros stockholders about 71.7%, and PIPE investors about 21.5%.
The transaction implies a valuation of $47.5 million for Werewolf and $500 million for Ambros. Werewolf's stock surged on the news, closing at $0.8735, up 102.7% from the previous close of $0.431, on volume of about 290 million shares versus an average of about 1.8 million.
The merger is expected to close after approvals from both companies' stockholders and other conditions, including the effectiveness of a Form S-4 registration statement and receipt of at least $100 million in PIPE proceeds.
Terms and structure
At closing, each share of Ambros common stock will be converted into shares of Werewolf common stock based on an exchange ratio. Ambros options will be assumed by Werewolf and converted into options for Werewolf stock. Ambros preferred stock will convert to Ambros common stock just before the merger.
The merger includes a contingent value right (CVR) for Werewolf stockholders: each share of Werewolf common stock held before closing will receive a nontransferable CVR representing the right to future cash payments from Werewolf's legacy drug programs, WTX-124 and WTX-330. These payments are uncertain, and holders may receive nothing if no proceeds are generated.
Support agreements: Werewolf executives and directors holding about 1.4% of Werewolf stock will vote in favor of the deal, and Ambros insiders holding about 71.3% of Ambros stock will support it. Ambros insiders also signed 180-day lock-up agreements restricting sales of the shares they receive.
The deal includes termination fees: Ambros may pay $20 million to Werewolf in certain circumstances, and Werewolf may pay $1.9 million to Ambros in others.
What this means
This filing is a Form 8-K, which companies use to disclose major events. The specific item here is 'Entry into a Material Definitive Agreement,' meaning the merger agreement. The form also serves as a Rule 425 communication, which is how companies announce mergers and solicit shareholder votes.
A reverse merger like this occurs when a smaller or less established public company acquires a private company, but the private company's owners end up controlling the combined entity. That is why Ambros stockholders will own about 72% of the combined company, even though Ambros is nominally the acquired company.
The pre-funded warrants have an exercise price of $0.001 per share, meaning they are deeply in the money and essentially equivalent to shares. They are subject to a beneficial ownership limit of 9.99% (or up to 19.99% with notice), which prevents any single holder from owning too much of the company.
Before the deal closes, Werewolf must file a Form S-4 with the SEC, which will include a proxy statement for Werewolf stockholders to vote on the share issuance, a reverse stock split, a name change, and other matters. Ambros stockholders will approve the deal by written consent. If all conditions are met, the merger should close, but there is no guarantee, and the stock price reaction reflects the market's assessment of the deal's value.
Sources
- Daily price and volume history
- 425 filed 2026-08-21
Information summarized by AI from the sources listed above. May contain errors — informational only, not investment advice.